2026-01575Notice

IMAAVY Bio-Product Patent Review Locked In

Published Date: 1/27/2026

Notice

Summary

The FDA has officially set the review period for IMAAVY, a human biological product, which helps the company extend its patent protection. If anyone thinks the dates are wrong, they have until March 30, 2026, to speak up. Also, people can challenge whether the company acted quickly enough during the review by July 27, 2026. This means more time and money could be on the line for the patent holder and competitors.

Analyzed Economic Effects

3 provisions identified: 3 benefits, 0 costs, 0 mixed.

Applicant requests 1,007‑day patent extension

In its patent-extension filing to the USPTO, Momenta Pharmaceuticals seeks 1,007 days of patent term extension for U.S. Patent No. 10,676,526 on IMAAVY. The FDA's regulatory‑period determination is part of the record the USPTO will use when calculating any actual extension.

FDA sets 2,453‑day review period

The FDA determined the regulatory review period for the biologic IMAAVY is 2,453 days in total: 2,209 days in the testing phase and 244 days in the approval phase. FDA verified the key dates as August 13, 2018 (IND effective), August 29, 2024 (BLA submission), and April 29, 2025 (approval); this determination establishes the maximum potential length of a patent extension.

IMAAVY approved for gMG in patients 12+

IMAAVY (nipocalimab-aahu) was approved by FDA on April 29, 2025 for treatment of generalized myasthenia gravis (gMG) in adult and pediatric patients 12 years of age and older who are anti‑AChR or anti‑MuSK antibody positive. That approval represents the first permitted commercial marketing or use of the product.

Your PRIA Score

Score Hidden

Personalized for You

How does this regulation affect your finances?

Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.

Free to start

Key Dates

Published Date
Comments Due
1/27/2026
3/30/2026

Department and Agencies

Department
Independent Agency
Agency
Health and Human Services Department
Food and Drug Administration
Source: View HTML
Back to Federal Register

Take It Personal

Get Your Personalized Policy View

Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.

Already have an account? Sign in